Literature DB >> 6713542

Systemic suppression of contact hypersensitivity by ultraviolet b radiation or methoxsalen/ultraviolet a radiation in the guinea pig.

W L Morison, M L Kripke.   

Abstract

Treatment of strain 2 guinea pigs with ultraviolet b (uvb) (280-320 nm) radiation or methoxsalen, followed by ultraviolet a (uva) (320-400 nm) radiation, decreased the contact hypersensitivity (CHS) reaction to sensitizing agents applied subsequently to unirradiated sites. The decreased reactivity could be transferred to syngeneic animals and appeared to be caused by antigen-specific suppressor T lymphocytes. Ultraviolet b irradiation of sensitized animals did not affect elicitation of CHS in unirradiated skin.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6713542     DOI： 10.1016/0008-8749(84)90298-3

Source DB:  PubMed          Journal:  Cell Immunol        ISSN： 0008-8749            Impact factor:   4.868


  4 in total

1.  Serotonin signalling is crucial in the induction of PUVA-induced systemic suppression of delayed-type hypersensitivity but not local apoptosis or inflammation of the skin.

Authors:  Peter Wolf; Scott N Byrne; Alberto Y Limon-Flores; Gerald Hoefler; Stephen E Ullrich
Journal:  Exp Dermatol       Date:  2016-04-18       Impact factor: 3.960

2.  Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers.

Authors:  A J Nataraj; H S Black; H N Ananthaswamy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

3.  Suppressive effects of ascorbate derivatives on ultraviolet-B-induced injury in HaCaT human keratinocytes.

Authors:  Shin Yasuda; Mikiro Tada; Koji Yamada; Kyoya Takahata
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Mar-Apr       Impact factor: 2.416

4.  Identification of the molecular target for the suppression of contact hypersensitivity by ultraviolet radiation.

Authors:  L A Applegate; R D Ley; J Alcalay; M L Kripke
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.